Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Liora ter Horst"'
Autor:
Liora ter Horst, Ingeborg E. van Zeggeren, Sabine E. Olie, I-PACE Study Group, Diederik van de Beek, Matthijs C. Brouwer
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Suspected central nervous system (CNS) infections may pose a diagnostic challenge, and often concern severely ill patients. We aim to identify predictors of unfavourable outcome to prioritize diagnostics and treatment improvements. Unfavoura
Externí odkaz:
https://doaj.org/article/6fe1cb4e7d5c45e592cdbcf82cff1ed6
Autor:
Sabine E. Olie, Ingeborg E. van Zeggeren, Liora ter Horst, I.-PACE Study Group, Diederik van de Beek, Matthijs C. Brouwer
Publikováno v:
BMC Neurology, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Seizures can be part of the clinical presentation of central nervous system (CNS) infections. We describe patients suspected of a neurological infection who present with a seizure and study diagnostic accuracy of clinical and labo
Externí odkaz:
https://doaj.org/article/4a37bd8d589942bb968a9ed6a98f70e4
Autor:
Ingeborg E. van Zeggeren, Liora ter Horst, Hans Heijst, Charlotte E. Teunissen, Diederik van de Beek, Matthijs C. Brouwer
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-7 (2022)
Abstract Diagnosing central nervous system (CNS) infections quickly is often difficult. Neurofilament light chain (NfL) is a component of the axonal cytoskeleton and identified as marker of neuronal damage in several CNS diseases. We evaluated the di
Externí odkaz:
https://doaj.org/article/421506f5cf37434cb2df70e74e76bcb5
Autor:
Alexander P J Vlaar, Martin Witzenrath, Pieter van Paassen, Leo M A Heunks, Bruno Mourvillier, Sanne de Bruin, Endry H T Lim, Matthijs C Brouwer, Pieter R Tuinman, José F K Saraiva, Gernot Marx, Suzana M Lobo, Rodrigo Boldo, Jesus A Simon-Campos, Alexander D Cornet, Anastasia Grebenyuk, Johannes M Engelbrecht, Murimisi Mukansi, Philippe G Jorens, Robert Zerbib, Simon Rückinger, Korinna Pilz, Renfeng Guo, Diederik van de Beek, Niels C Riedemann, Alexander P.J. Vlaar, Leo M.A. Heunks, Endry H.T. Lim, Matthijs C. Brouwer, Pieter R. Tuinman, José Francisco K. Saraiva, Suzana Lobo, Jesus Simon-Campos, Alexander D. Cornet, Johannes Engelbrecht, Philippe G. Jorens, Niels C. Riedemann, Pierre Bulpa, Fabio S. Taccone, Greet Hermans, Marc Diltoer, Michael Piagnerelli, Nikolaas De Neve, Antonio T. Freire, Felipe D. Pizzol, Anna Karolina Marinho, Victor H. Sato, Clovis Arns da Cunha, Mathilde Neuville, Jean Dellamonica, Djillali Annane, Antoine Roquilly, Jean Luc Diehl, Francis Schneider, Jean Paul Mira, Jean Baptiste Lascarrou, Luc Desmedt, Claire Dupuis, Carole Schwebel, Guillaume Thiéry, Matthias Gründling, Marc Berger, Tobias Welte, Michael Bauer, Ulrich Jaschinski, Klaus Matschke, Roberto Mercado-Longoria, Belinda Gomez Quintana, Jorge Alberto Zamudio-Lerma, Juan Moreno Hoyos Abril, Angel Aleman Marquez, Peter Pickkers, Luuk Otterspoor, Luis Hercilla Vásquez, Carlos Rafael Seas Ramos, Alejandro Peña Villalobos, Gonzalo Gianella Malca, Victoria Chávez, Victor Filimonov, Vladimir Kulabukhov, Pinak Acharya, Sjoerd A.M.E.G. Timmermans, Matthias H. Busch, Floor L.F. van Baarle, Rutger Koning, Liora ter Horst, Nora Chekrouni, Thijs M. van Soest, Marleen A. Slim, Lonneke A. van Vught, Rombout B.E. van Amstel, Sabine E. Olie, Ingeborg E. van Zeggeren, Marcel C.G. van de Poll, Claus Thielert, Dorothee Neukirchen
Publikováno v:
The Lancet Respiratory medicine, 10(12), 1137-1146. ELSEVIER SCI LTD
Lancet respiratory medicine, 10(12), 1137-1146. Elsevier Limited
Lancet Respiratory Medicine, 10, 12, pp. 1137-1146
The lancet respiratory medicine
PANAMO study group 2022, ' Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO) : a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial ', Lancet respiratory medicine, vol. 10, no. 12, pp. 1137-1146 . https://doi.org/10.1016/S2213-2600(22)00297-1
lancet. Respiratory medicine, 10(12), 1137-1146. Elsevier Limited
Lancet Respiratory Medicine, 10, 1137-1146
Lancet respiratory medicine, 10(12), 1137-1146. Elsevier Limited
Lancet Respiratory Medicine, 10, 12, pp. 1137-1146
The lancet respiratory medicine
PANAMO study group 2022, ' Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO) : a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial ', Lancet respiratory medicine, vol. 10, no. 12, pp. 1137-1146 . https://doi.org/10.1016/S2213-2600(22)00297-1
lancet. Respiratory medicine, 10(12), 1137-1146. Elsevier Limited
Lancet Respiratory Medicine, 10, 1137-1146
Contains fulltext : 287661.pdf (Publisher’s version ) (Closed access) BACKGROUND: Vilobelimab, an anti-C5a monoclonal antibody, was shown to be safe in a phase 2 trial of invasively mechanically ventilated patients with COVID-19. Here, we aimed to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f8ba6e900c408360d398f60555ae06e
https://cris.maastrichtuniversity.nl/en/publications/bd6096d8-38fc-4032-bed0-e61be7ec1575
https://cris.maastrichtuniversity.nl/en/publications/bd6096d8-38fc-4032-bed0-e61be7ec1575
Publikováno v:
Clinical infectious diseases, 73(9), E2545-E2551. Oxford University Press
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Background Recurrent bacterial meningitis has been found to occur in about 5% of meningitis cases. Methods We analyzed adults with recurrent episodes in a prospective nationwide cohort study of community-acquired bacterial meningitis. Results Of 2264
Autor:
Thijs M, van Soest, Liora Ter, Horst, Nora, Chekrouni, Merijn W, Bijlsma, Matthijs C, Brouwer, Daniela Urueta, Portillo, Diederik, van de Beek, Rodrigo, Hasbun
Publikováno v:
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
We aimed to derive and validate a risk score to differentiate patients with bacterial meningitis from those with viral meningitis or encephalitis, among patients presenting with CSF leukocytosis and a negative Gram stain.We included adults with bacte
Autor:
Arie van der Ende, Liora ter Horst, Merijn W Bijlsma, Matthijs C. Brouwer, Diederik L.H. Koelman, Diederik van de Beek
Publikováno v:
Clinical Infectious Diseases, 74(4), 657-667. Oxford University Press
Clinical infectious diseases, 74(4), 657-667. Oxford University Press
Koelman, D L H, Brouwer, M C, ter Horst, L, Bijlsma, M W, van der Ende, A & van de Beek, D 2022, ' Pneumococcal Meningitis in Adults : A Prospective Nationwide Cohort Study over a 20-year Period ', Clinical Infectious Diseases, vol. 74, no. 4, pp. 657-667 . https://doi.org/10.1093/cid/ciab477
Clinical infectious diseases, 74(4), 657-667. Oxford University Press
Koelman, D L H, Brouwer, M C, ter Horst, L, Bijlsma, M W, van der Ende, A & van de Beek, D 2022, ' Pneumococcal Meningitis in Adults : A Prospective Nationwide Cohort Study over a 20-year Period ', Clinical Infectious Diseases, vol. 74, no. 4, pp. 657-667 . https://doi.org/10.1093/cid/ciab477
Background The epidemiology and treatment of pneumococcal meningitis has changed with the implementation of conjugate vaccines and the introduction of adjunctive dexamethasone therapy. Methods We analyzed episodes of community-acquired pneumococcal m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25613ceab4eb7ae820fa3d7622361284
https://research.vumc.nl/en/publications/c82a9865-2ac9-42f9-936e-521023a2e123
https://research.vumc.nl/en/publications/c82a9865-2ac9-42f9-936e-521023a2e123
Autor:
Thijs M. van Soest, Liora ter Horst, Nora Chekrouni, Merijn W. Bijlsma, Matthijs C. Brouwer, Daniela Urueta Portillo, Diederik van de Beek, Rodrigo Hasbun
Publikováno v:
Clinical Microbiology and Infection
Clinical microbiology and infection. Elsevier Limited
van Soest, T M, Horst, L T, Chekrouni, N, Bijlsma, M W, Brouwer, M C, Portillo, D U, van de Beek, D & Hasbun, R 2022, ' A risk score for identifying patients at a low risk of bacterial meningitis amongst adults with cerebrospinal fluid leucocytosis and a negative gram stain result : a derivation and validation study ', Clinical Microbiology and Infection . https://doi.org/10.1016/j.cmi.2022.10.001
Clinical microbiology and infection. Elsevier Limited
van Soest, T M, Horst, L T, Chekrouni, N, Bijlsma, M W, Brouwer, M C, Portillo, D U, van de Beek, D & Hasbun, R 2022, ' A risk score for identifying patients at a low risk of bacterial meningitis amongst adults with cerebrospinal fluid leucocytosis and a negative gram stain result : a derivation and validation study ', Clinical Microbiology and Infection . https://doi.org/10.1016/j.cmi.2022.10.001
Objectives: We aimed to derive and validate a risk score to differentiate patients with bacterial meningitis from those with viral meningitis or encephalitis amongst patients presenting with cerebrospinal fluid (CSF) leucocytosis and a negative Gram
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::902bc6cb6caffef22e31cd1e5b31b705
https://research.vumc.nl/en/publications/e6ffe7d2-95af-4997-9185-0bb9fdb2ad4d
https://research.vumc.nl/en/publications/e6ffe7d2-95af-4997-9185-0bb9fdb2ad4d
Publikováno v:
Clinical infectious diseases, 70(11), 2256-2261. Oxford University Press
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Background Cerebrospinal fluid (CSF) leakage is a risk factor for developing bacterial meningitis. Methods We analyzed episodes of community-acquired bacterial meningitis associated with CSF leakage from a prospective nationwide cohort study. Results
Autor:
Leo M. A. Heunks, Frank E.H.P. van Baarle, Lieuwe D. J. Bos, Frederique Paulus, Esther B. Bulle, Simon Rueckinger, Marcus J. Schultz, Matthijs C. Brouwer, Pieter van Paassen, Janneke Horn, Martin Witzenrath, Ingeborg E. van Zeggeren, E. Marleen Kemper, W. Joost Wiersinga, Marcel C. G. van de Poll, Sjoerd A.M.E.G. Timmermans, Rutger Koning, Korinna Pilz, Niels C. Riedemann, Alexander P.J. Vlaar, Diederik van de Beek, Iwan C. C. van der Horst, Matthias Busch, Sanne de Bruin, Liora ter Horst, Ren Feng Guo
Publikováno v:
The Lancet Rheumatology, 2(12), e764-e773. Lancet Publishing Group
The Lancet Rheumatology, 2(12), E764-E773. Lancet Publishing Group
Vlaar, A P J, de Bruin, S, Busch, M, Timmermans, S A M E G, van Zeggeren, I E, Koning, R, Ter Horst, L, Bulle, E B, van Baarle, F E H P, van de Poll, M C G, Kemper, E M, van der Horst, I C C, Schultz, M J, Horn, J, Paulus, F, Bos, L D, Wiersinga, W J, Witzenrath, M, Rueckinger, S, Pilz, K, Brouwer, M C, Guo, R-F, Heunks, L, van Paassen, P, Riedemann, N C & van de Beek, D 2020, ' Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO) : an exploratory, open-label, phase 2 randomised controlled trial ', The Lancet Rheumatology, vol. 2, no. 12, pp. e764-e773 . https://doi.org/10.1016/S2665-9913(20)30341-6
The Lancet Rheumatology
The Lancet Rheumatology, 2(12), E764-E773. Lancet Publishing Group
Vlaar, A P J, de Bruin, S, Busch, M, Timmermans, S A M E G, van Zeggeren, I E, Koning, R, Ter Horst, L, Bulle, E B, van Baarle, F E H P, van de Poll, M C G, Kemper, E M, van der Horst, I C C, Schultz, M J, Horn, J, Paulus, F, Bos, L D, Wiersinga, W J, Witzenrath, M, Rueckinger, S, Pilz, K, Brouwer, M C, Guo, R-F, Heunks, L, van Paassen, P, Riedemann, N C & van de Beek, D 2020, ' Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO) : an exploratory, open-label, phase 2 randomised controlled trial ', The Lancet Rheumatology, vol. 2, no. 12, pp. e764-e773 . https://doi.org/10.1016/S2665-9913(20)30341-6
The Lancet Rheumatology
Background Severe COVID-19 is characterised by inflammation and coagulation in the presence of complement system activation. We aimed to explore the potential benefit and safety of selectively blocking the anaphylatoxin and complement protein C5a wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7a3cabed40314643ba9bb8842abe17e
https://pure.amc.nl/en/publications/antic5a-antibody-ifx1-vilobelimab-treatment-versus-best-supportive-care-for-patients-with-severe-covid19-panamo(1f96aacf-dec4-4976-90c4-4807fe469d43).html
https://pure.amc.nl/en/publications/antic5a-antibody-ifx1-vilobelimab-treatment-versus-best-supportive-care-for-patients-with-severe-covid19-panamo(1f96aacf-dec4-4976-90c4-4807fe469d43).html